EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitNetzwerk-Metaanalyse

Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis

Fausto Petrelli, Sara Cherri, Michele Ghidini, Gianluca Tomasello, Antonio Ghidini, Alberto Zaniboni

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2023.06.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Fausto Petrelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, ASST Bergamo Ovest, Treviglio (BG), Italy. Electronic address: faupe@libero.it. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In metastatic RAS wild-type colorectal cancer (CRC), induction combination chemotherapy doublets (CT) with an anti-EGFR agent are considered the primary treatment. We performed a network meta-analysis (NMA) to compare the relative efficacy of different maintenance treatments for advanced RAS wild-type CRC. MATERIALS AND METHODS: PubMed, EMBASE and Cochrane, from database inception until December 2021 were used. Randomized clinical trials enrolling adults with advanced RAS wild-type CRC and providing overall survival (OS) and/or progression-free survival (PFS) data PRISMA guidelines for NMA were followed. Between-group comparisons were estimated using hazard ratios (HRs) with 95% credible intervals (95% CrIs). Agents were ranked using surface under the cumulative ranking (SUCRA) probabilities. RESULTS: A total of 7 randomized phase 2 trials were included (for a total of 1286 patients). Compared to depotentiation treatments, continuous CT + anti-EGFR was not significantly superior to other maintenance regimens for OS and was ranked as the best option for NMA (SUCRA p-score=0.69). Conversely, in the PFS analysis, single-agent fluoropyrimidines + anti-EGFR was ranked as the best treatment (SUCRA p-score=0.60). CONCLUSIONS: Maintaining chemotherapy doublet + anti-EGFR until progression appears to be the best first-line strategy in terms of OS for advanced unresectable RAS wild-type mCRC treatment. However, fluoropyrimidines single-agent + cetuximab or panitumumab represent a reasonable choice regarding PFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsAdultHumansPanitumumabCetuximabAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Colorectal cancerMaintenance therapyNetwork meta-analysisRAS wild-type

Substanzen

PanitumumabCetuximab

Autor:innen und Institutionen

  • Oncology Unit, ASST Bergamo Ovest, Treviglio (BG), Italy. Electronic address: faupe@libero.it.
  • Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.
  • Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Oncology Unit, casa di cura Igea, Milano, Italy.

Zitieren

APA

Petrelli, F., Cherri, S., Ghidini, M., Tomasello, G., Ghidini, A., & Zaniboni, A. (2024). Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.06.008

Vancouver

Petrelli F, Cherri S, Ghidini M, Tomasello G, Ghidini A, Zaniboni A. Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.06.008

BibTeX
@article{Petrelli2024,
  author = {Petrelli, Fausto and Cherri, Sara and Ghidini, Michele and Tomasello, Gianluca and Ghidini, Antonio and Zaniboni, Alberto},
  title = {Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2023.06.008}
}
Kostenlos starten →